Drug Profile
LX 1033
Alternative Names: LX-1033Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-I for Irritable bowel syndrome (In volunteers) in USA (PO)
- 08 Sep 2021 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome(In volunteers) in USA (PO, Capsule)